Amsbio has announced the RPMotion, a spinning organoid bioreactor designed to simplify and accelerate organoid culture for applications including drug discovery, disease modelling, and regenerative medicine.

Traditionally, organoid expansion has relied on static culture methods that are resource-intensive and time-consuming. The RPMotion aims to address these challenges with a novel design that reduces manual intervention while improving scalability and consistency.

Accelerating Organoid Expansion While Reducing Costs

The RPMotion is optimized for automated small-scale expansion and differentiation (5–50 mL), enabling laboratories to significantly increase throughput without increasing workload.

According to Amsbio, the system delivers measurable efficiency gains:

• Up to 5-fold faster organoid expansion compared to conventional methods
• Approximately 60% reduction in culture ingredient costs
• Up to 75% reduction in labor requirements
• Minimal hands-on time with monitoring possible without opening the incubator

These improvements position the system as a practical solution for labs seeking to scale organoid workflows while maintaining budget control.

Designed for Automation and Parallel Workflows

The compact RPMotion is controlled via an external LCD interface, allowing users to select and cycle through protocols tailored to specific organoid types. Its multiplex capability enables four tubes to run simultaneously, supporting parallel experimentation.

To further enhance scalability, up to 28 additional bioreactors can be connected through a plug-and-play setup and controlled from a single interface. This design supports growing labs that need flexible expansion without complex infrastructure changes.

Supporting Consistency and GMP-Aligned Applications

Beyond productivity gains, the RPMotion is engineered to produce consistent, high-quality organoids. This makes it particularly relevant for laboratories working toward standardized processes and GMP-aligned workflows.

By improving reproducibility and reducing variability, the system supports downstream applications where quality and consistency are critical.

Enabling Next-Generation Cell Culture Workflows

Amsbio, part of the Europa Biosite group, continues to expand its portfolio of advanced cell culture and 3D model technologies. With expertise spanning stem cells, extracellular matrices, and cryopreservation, the company supports researchers from early discovery through to clinical and GMP-ready stages.

The introduction of the RPMotion reflects ongoing demand for automated, scalable solutions that reduce bottlenecks in organoid research while improving experimental reliability.

For laboratories seeking to modernize their organoid culture workflows, the RPMotion offers a combination of speed, efficiency, and scalability aligned with current research and translational needs.